Caris Life Sciences, an Irving, Texas-based innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, raised $830m in growth equity funding at a post-money valuation of $7.83 billion.
The round was led by Sixth Street, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Silver Lake, Fidelity Management & Research Company LLC, Coatue, Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corporation, Eaton Vance Equity (Morgan Stanley), Pura Vida Investments and First Light Asset Management.
Led by David D. Halbert, Chairman and CEO, Caris Life Sciences is an innovator in molecular science and artificial intelligence focused on precision medicine. The company’s suite of molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make personalized treatment decisions.
Caris is also advancing precision medicine with Caris Artificial Intelligence, combining its service offering, Caris Molecular Intelligence® with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides molecular solutions for patients, physicians, payers and biopharmaceutical organizations.
Headquartered in Irving, Texas, the company has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets.